Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeu...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.45-51 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | |
| container_start_page | 45 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 104 |
| creator | Paz-Ares, Luis G Zimmermann, Annamaria Ciuleanu, Tudor Bunn, Paul A Antonio, Belen San Denne, Jonathan Iturria, Nancy John, William Scagliotti, Giorgio V |
| description | Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeutic settings. • Overall, our results support the effectiveness of pemetrexed in fit elderly patients. • Our findings support evidence indicating that age alone should not dictate lung cancer treatment. |
| doi_str_mv | 10.1016/j.lungcan.2016.12.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869968544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500216305578</els_id><sourcerecordid>1869968544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-dea4c8cc34d2cf9bbd995073b98fe7d119983bb23127111317cc66d653a2868b3</originalsourceid><addsrcrecordid>eNqFUsuO1DAQtBCInV34BJCPXBL8yMO-gNAKFqRFHICz5TidWQ-JPWs7Yecr-GUcZeDAhYutVld1d3U1Qi8oKSmhzetDOc5ub7QrWQ5LykpC2kdoR0XLCsE5e4x2OSGLmhB2gS5jPBBCW0rkU3TBBKNMSrlDvz5D0oV2ejxFGzE86Mk66_bYTkdtEvYD1nvA3mG_QNDjiOMcFrvoEf-06Q4fYYIU4AF6PPiA0x3gHOo0gdvI_aKdyVnnXRHvZz35OW7BtFYzkJ9VCTYrLjxDTwY9Rnh-_q_Q9w_vv11_LG6_3Hy6fndbmIqRVPSgKyOM4VXPzCC7rpeyJi3vpBig7SmVUvCuY5yyllLKaWtM0_RNzTUTjej4FXq11T0Gfz9DTGqycR1GO8gTKioaKRtRV1WG1hvUBB9jgEEdg510OClK1OqFOqizF2r1QlGmsheZ9_LcYu4m6P-y_iw_A95uAMhCFwtBRWNh3ZYNYJLqvf1vizf_VDBjts_o8QecIB78HLKzWY2KmaC-rgex3gNtOKnrVvDfSaG09g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869968544</pqid></control><display><type>article</type><title>Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Paz-Ares, Luis G ; Zimmermann, Annamaria ; Ciuleanu, Tudor ; Bunn, Paul A ; Antonio, Belen San ; Denne, Jonathan ; Iturria, Nancy ; John, William ; Scagliotti, Giorgio V</creator><creatorcontrib>Paz-Ares, Luis G ; Zimmermann, Annamaria ; Ciuleanu, Tudor ; Bunn, Paul A ; Antonio, Belen San ; Denne, Jonathan ; Iturria, Nancy ; John, William ; Scagliotti, Giorgio V</creatorcontrib><description>Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeutic settings. • Overall, our results support the effectiveness of pemetrexed in fit elderly patients. • Our findings support evidence indicating that age alone should not dictate lung cancer treatment.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2016.12.007</identifier><identifier>PMID: 28212999</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Advanced non-small cell lung cancer ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Cisplatin - therapeutic use ; Clinical Trials, Phase III as Topic ; Disease-Free Survival ; Elderly ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - epidemiology ; Lung Neoplasms - mortality ; Meta-analysis ; Overall survival ; Pemetrexed ; Pemetrexed - therapeutic use ; Platinum - therapeutic use ; Pulmonary/Respiratory ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.45-51</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-dea4c8cc34d2cf9bbd995073b98fe7d119983bb23127111317cc66d653a2868b3</citedby><cites>FETCH-LOGICAL-c420t-dea4c8cc34d2cf9bbd995073b98fe7d119983bb23127111317cc66d653a2868b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2016.12.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28212999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paz-Ares, Luis G</creatorcontrib><creatorcontrib>Zimmermann, Annamaria</creatorcontrib><creatorcontrib>Ciuleanu, Tudor</creatorcontrib><creatorcontrib>Bunn, Paul A</creatorcontrib><creatorcontrib>Antonio, Belen San</creatorcontrib><creatorcontrib>Denne, Jonathan</creatorcontrib><creatorcontrib>Iturria, Nancy</creatorcontrib><creatorcontrib>John, William</creatorcontrib><creatorcontrib>Scagliotti, Giorgio V</creatorcontrib><title>Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeutic settings. • Overall, our results support the effectiveness of pemetrexed in fit elderly patients. • Our findings support evidence indicating that age alone should not dictate lung cancer treatment.</description><subject>Advanced non-small cell lung cancer</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Cisplatin - therapeutic use</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Disease-Free Survival</subject><subject>Elderly</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Lung Neoplasms - mortality</subject><subject>Meta-analysis</subject><subject>Overall survival</subject><subject>Pemetrexed</subject><subject>Pemetrexed - therapeutic use</subject><subject>Platinum - therapeutic use</subject><subject>Pulmonary/Respiratory</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQtBCInV34BJCPXBL8yMO-gNAKFqRFHICz5TidWQ-JPWs7Yecr-GUcZeDAhYutVld1d3U1Qi8oKSmhzetDOc5ub7QrWQ5LykpC2kdoR0XLCsE5e4x2OSGLmhB2gS5jPBBCW0rkU3TBBKNMSrlDvz5D0oV2ejxFGzE86Mk66_bYTkdtEvYD1nvA3mG_QNDjiOMcFrvoEf-06Q4fYYIU4AF6PPiA0x3gHOo0gdvI_aKdyVnnXRHvZz35OW7BtFYzkJ9VCTYrLjxDTwY9Rnh-_q_Q9w_vv11_LG6_3Hy6fndbmIqRVPSgKyOM4VXPzCC7rpeyJi3vpBig7SmVUvCuY5yyllLKaWtM0_RNzTUTjej4FXq11T0Gfz9DTGqycR1GO8gTKioaKRtRV1WG1hvUBB9jgEEdg510OClK1OqFOqizF2r1QlGmsheZ9_LcYu4m6P-y_iw_A95uAMhCFwtBRWNh3ZYNYJLqvf1vizf_VDBjts_o8QecIB78HLKzWY2KmaC-rgex3gNtOKnrVvDfSaG09g</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Paz-Ares, Luis G</creator><creator>Zimmermann, Annamaria</creator><creator>Ciuleanu, Tudor</creator><creator>Bunn, Paul A</creator><creator>Antonio, Belen San</creator><creator>Denne, Jonathan</creator><creator>Iturria, Nancy</creator><creator>John, William</creator><creator>Scagliotti, Giorgio V</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer</title><author>Paz-Ares, Luis G ; Zimmermann, Annamaria ; Ciuleanu, Tudor ; Bunn, Paul A ; Antonio, Belen San ; Denne, Jonathan ; Iturria, Nancy ; John, William ; Scagliotti, Giorgio V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-dea4c8cc34d2cf9bbd995073b98fe7d119983bb23127111317cc66d653a2868b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Advanced non-small cell lung cancer</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Cisplatin - therapeutic use</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Disease-Free Survival</topic><topic>Elderly</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Lung Neoplasms - mortality</topic><topic>Meta-analysis</topic><topic>Overall survival</topic><topic>Pemetrexed</topic><topic>Pemetrexed - therapeutic use</topic><topic>Platinum - therapeutic use</topic><topic>Pulmonary/Respiratory</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paz-Ares, Luis G</creatorcontrib><creatorcontrib>Zimmermann, Annamaria</creatorcontrib><creatorcontrib>Ciuleanu, Tudor</creatorcontrib><creatorcontrib>Bunn, Paul A</creatorcontrib><creatorcontrib>Antonio, Belen San</creatorcontrib><creatorcontrib>Denne, Jonathan</creatorcontrib><creatorcontrib>Iturria, Nancy</creatorcontrib><creatorcontrib>John, William</creatorcontrib><creatorcontrib>Scagliotti, Giorgio V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paz-Ares, Luis G</au><au>Zimmermann, Annamaria</au><au>Ciuleanu, Tudor</au><au>Bunn, Paul A</au><au>Antonio, Belen San</au><au>Denne, Jonathan</au><au>Iturria, Nancy</au><au>John, William</au><au>Scagliotti, Giorgio V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>104</volume><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeutic settings. • Overall, our results support the effectiveness of pemetrexed in fit elderly patients. • Our findings support evidence indicating that age alone should not dictate lung cancer treatment.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>28212999</pmid><doi>10.1016/j.lungcan.2016.12.007</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.45-51 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869968544 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Advanced non-small cell lung cancer Age Factors Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cisplatin - therapeutic use Clinical Trials, Phase III as Topic Disease-Free Survival Elderly Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - epidemiology Lung Neoplasms - mortality Meta-analysis Overall survival Pemetrexed Pemetrexed - therapeutic use Platinum - therapeutic use Pulmonary/Respiratory Retrospective Studies Treatment Outcome |
| title | Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A49%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meta-analysis%20examining%20impact%20of%20age%20on%20overall%20survival%20with%20pemetrexed%20for%20the%20treatment%20of%20advanced%20non-squamous%20non-small%20cell%20lung%20cancer&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Paz-Ares,%20Luis%20G&rft.date=2017-02-01&rft.volume=104&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2016.12.007&rft_dat=%3Cproquest_cross%3E1869968544%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1869968544&rft_id=info:pmid/28212999&rft_els_id=S0169500216305578&rfr_iscdi=true |